Abstract: Letters to the Editor
e579
Queen Mary University of London
London, United Kingdom
The authors have no conflicts of interest to declare.
REFERENCES
1. Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for
prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to
inform clinical guidelines. Am J Ther. 2021;28:e434–e460.
2. Roman YM, Burela PA, Pasupuleti V, et al. Ivermectin for
the treatment of COVID-19: a systematic review and metaanalysis of randomized controlled trials.,Clin Infect Dis. 2021;
ciab591. doi: 10.1093/cid/ciab591.
3. Crawford M. The Meta-Analytical Fixers: An Ivermectin
Tale; 2021. Available at: https://roundingtheearth.
substack.com/p/the-meta-analytical-fixers-anivermectin. Accessed July 7, 2021.
4. Neil M, Fenton NE, Bayesian Hypothesis Testing and Hierarchical Modelling of Ivermectin Effectiveness in Treating
Covid-19, 2021. Available at: http://dx.doi.org/10.
13140/RG.2.2.19703.75680.
5. Niaee MS, Gheibi N, Namdar P, et al. Ivermectin as an
adjunct treatment for hospitalized adult COVID-19 patients: a randomized multi-center clinical trial. Asian Pac
J Trop Med. 2021;14:266.
6. Elgazzar A, Hany B, Youssef SA, et al. Efficacy and Safety of
Ivermectin for Treatment and Prophylaxis of COVID-19 Pandemic; 2020. Available at: https://www.researchsquare.
com/article/rs-100956/v2.
Ivermectin, A Reanalysis of the Data
To the Editor:
Our article entitled “Review of the Emerging Evidence Demonstrating the Efficacy of Ivermectin in the
Prophylaxis and Treatment of COVID-19” was recently
published in the American Journal of Therapeutics.1 Our
article included randomized and observational trial
meta-analyses on the efficacy of ivermectin for the prophylaxis and treatment of COVID-19. Recently, the
study conducted by Elgazzar et al2 has come under
scrutiny with accusations of scientific misconduct. His
paper was apparently retracted without his knowledge
and without giving him the opportunity to defend these
serious claims. This situation is most unfortunate. While
this issue is being resolved, we decided to redo the
original meta-analyses excluding this study. The summary point estimates were largely unaffected when the
study by Elgazzar et al was removed. The revised forest
plots are provided below (Figures 1–3).
FIGURE 1. Meta-analysis of ivermectin prophylaxis trials in COVID-19. Symbols: Squares indicate treatment effect of an
individual study. Large diamond reflects summary of study design immediately above. Size of each symbol correlates
with the size of the CI around the point estimate of treatment effect with larger sizes indicating a more precise CI. CI,
confidence interval; OBS, observational study; RCT, randomized controlled trial.
www.americantherapeutics.com
American Journal of Therapeutics (2021) 28(5)
Copyright © 2021 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
e580
Letters to the Editor
FIGURE 2. Meta-analysis of the outcome of time to clinical recovery from controlled trials of ivermectin treatment in COVID19. Symbols: Squares indicate treatment effect of an individual study. Large diamond reflects summary of study design
immediately above. Small diamond indicates sum effect of all trial designs. Size of each symbol correlates with the size of
the CI around the point estimate of treatment effect with larger sizes indicating a more precise CI. CI, confidence interval.
FIGURE 3. Meta-analysis of the..
DOI record:
{
"DOI": "10.1097/mjt.0000000000001443",
"ISSN": [
"1075-2765"
],
"URL": "http://dx.doi.org/10.1097/MJT.0000000000001443",
"author": [
{
"affiliation": [
{
"name": "Eastern Virginia Medical School, Norfolk, VA"
}
],
"family": "Marik",
"given": "Paul E.",
"sequence": "first"
},
{
"ORCID": "http://orcid.org/0000-0002-0816-9682",
"affiliation": [
{
"name": "Front Line Covid 19 Critical Care Alliance, Madison, WI"
}
],
"authenticated-orcid": false,
"family": "Kory",
"given": "Pierre",
"sequence": "additional"
}
],
"container-title": "American Journal of Therapeutics",
"content-domain": {
"crossmark-restriction": false,
"domain": []
},
"created": {
"date-parts": [
[
2021,
9,
7
]
],
"date-time": "2021-09-07T20:00:36Z",
"timestamp": 1631044836000
},
"deposited": {
"date-parts": [
[
2023,
9,
17
]
],
"date-time": "2023-09-17T04:18:52Z",
"timestamp": 1694924332000
},
"indexed": {
"date-parts": [
[
2024,
3,
8
]
],
"date-time": "2024-03-08T12:30:46Z",
"timestamp": 1709901046798
},
"is-referenced-by-count": 7,
"issue": "5",
"issued": {
"date-parts": [
[
2021,
9
]
]
},
"journal-issue": {
"issue": "5",
"published-online": {
"date-parts": [
[
2021
]
]
}
},
"language": "en",
"link": [
{
"URL": "https://journals.lww.com/10.1097/MJT.0000000000001443",
"content-type": "unspecified",
"content-version": "vor",
"intended-application": "similarity-checking"
}
],
"member": "276",
"original-title": [],
"page": "e579-e580",
"prefix": "10.1097",
"published": {
"date-parts": [
[
2021,
9
]
]
},
"published-online": {
"date-parts": [
[
2021,
9
]
]
},
"publisher": "Ovid Technologies (Wolters Kluwer Health)",
"reference": [
{
"DOI": "10.1097/MJT.0000000000001377",
"article-title": "Review of the emerging evidence demonstrating the efficacy of ivermectin in the prophylaxis and treatment of COVID-19",
"author": "Kory",
"doi-asserted-by": "crossref",
"first-page": "e299",
"journal-title": "Am J Ther.",
"key": "R1-20230917",
"volume": "28",
"year": "2020"
},
{
"article-title": "Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic",
"author": "Elgazzar",
"journal-title": "Research Square.",
"key": "R2-20230917",
"year": "2020"
}
],
"reference-count": 2,
"references-count": 2,
"relation": {},
"resource": {
"primary": {
"URL": "https://journals.lww.com/10.1097/MJT.0000000000001443"
}
},
"score": 1,
"short-title": [],
"source": "Crossref",
"subject": [],
"subtitle": [],
"title": "Ivermectin, A Reanalysis of the Data",
"type": "journal-article",
"volume": "28"
}
